Recent Advances for Targeted Therapies in Glioblastoma

Michael Youssef, Jacob Mandel, Sajeel Chowdhary, Santosh Kesari

Research output: Chapter in Book/Report/Conference proceedingChapter


Glioblastoma (GBM) is the most common primary brain tumors in adults. Despite aggressive multimodality therapies, GBM unfortunately remains among the most resistant cancers to treatment. In the past, traditional chemotherapy which works by impeding DNA synthesis or cell metabolism has been used to try and slow the progression of GBM with little success. Recently, research has become more focused into the development of targeted therapies in which drugs (small molecules or antibodies) effect specific molecular and genetic alterations in GBM attempting to inhibit and deregulate cell signaling pathways. The Cancer Genome Atlas (TCGA) GBM project has provided an in depth description of the distinct molecular and genetic alterations in GBM stimulating interest in the development of targeted molecular therapies. While the results of targeted therapy studies to date have failed to improve the overall survival of GBM patients, there continues to be enthusiasm in this approach with numerous clinical trials currently underway. Hopefully, knowledge from the previous failed trials will help provide further insight and assist future clinicians in designing new novel targeted treatments to overcome these barriers.

Original languageEnglish (US)
Title of host publicationCurrent Cancer Research
PublisherSpringer Nature
Number of pages25
StatePublished - 2017
Externally publishedYes

Publication series

NameCurrent Cancer Research
ISSN (Print)2199-2584
ISSN (Electronic)2199-2592


  • Glioblastoma
  • p53 pathway
  • Receptor tyrosine kinase pathway
  • Retinoblastoma pathway
  • targeted therapy
  • The Cancer Genome Atlas

ASJC Scopus subject areas

  • Cancer Research
  • Oncology


Dive into the research topics of 'Recent Advances for Targeted Therapies in Glioblastoma'. Together they form a unique fingerprint.

Cite this